Bliss GVS Pharma Quarterly Results

Charts

YoY Net Sales (Quarterly)

Operating Margin

EPS Growth

POSITIVES

Revenue increased to ₹211.88 Crore in Q3 FY2023, showing a robust upward trend from previous quarters.
Operating profit margin improved significantly to 21.96% in Q3 FY2023, highlighting operational efficiency.
Net profit for Q3 FY2023 rebounded to ₹43.04 Crore, marking a significant recovery from a loss in Q4 FY2022.

NEGATIVES

Expenses rose to ₹165.35 Crore in Q3 FY2023, which could pressure profit margins going forward.
Profit before tax decreased to ₹59.13 Crore in Q3 FY2023 compared to previous quarters, indicating potential challenges ahead.
Other income dropped significantly in Q3 FY2023 to ₹12.60 Crore, impacting overall profitability.

Field	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25
Revenue	159.52	211.88	200.72	198.13	183.64	217.68	210.42	197.99	207.47
Expenses	135.31	157.51	157.02	169.78	149.31	176.20	180.63	176.90	166.14
Operating Profit	24.21	54.37	43.69	28.35	34.33	41.48	29.79	21.09	41.33
Other Income	5.11	12.60	5.42	5.60	4.12	5.04	15.27	12.07	35.45
Interest	1.49	1.45	2.12	1.85	1.53	3.83	1.08	1.68	5.47
Depreciation	6.19	6.39	6.95	6.85	6.85	6.98	7.55	8.04	8.20
Profit Before Tax	21.64	59.13	40.05	-3.95	30.07	35.71	36.42	23.44	63.11
Tax	7.27	16.09	10.97	0.97	7.97	10.01	10.62	6.79	18.75
Net Profit	14.37	43.04	29.07	-4.91	22.11	25.69	25.80	16.65	44.36
Eps in Rs	1.41	4.06	2.64	-0.88	1.97	2.31	2.27	1.47	4.08